beta

AKTX

Akari Therapeutics Plc

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.

Market Cap: 64.4 Million

Primary Exchange: NASDAQ

Website: http://akaritx.com

Shares Outstanding: 28.7 Million

Float: 28.3 Million

Dividend: (%)

Beta: 0.675343501119608

Sector: Health Technology

Industry: Pharmaceuticals: Major

Ethical Flags

Longest drawdown: 2128 trading days

From: 2014-01-15 To: 2020-07-02

Lowest Point:

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
2015-09-17 10.0 1.0 10.0
Data provided by IEX Cloud